Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.

Drug Des Devel Ther · 2018 · PMC6237136 · PMID 30518998

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an important trendno p-value reported

1 Of interest, the gene expression profile of psoriatic lesions showed an important trend of normalization similar to that of non-lesional skin after treatment. 1 In terms of safety, 24 weeks after initiation of treatment, 65% of patients (20/31) receiving risankizumab intravenously or subcutaneously had an adverse event compared to 88% of patients (7/8) receiving placebo. 1 Of note, th

also in 1,052 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.